Резюме
Определение
Анамнез и осмотр
Ключевые диагностические факторы
- palidez
- equimosis o petequias
Другие диагностические факторы
- fatiga
- mareos
- palpitaciones
- disnea
- infecciones o fiebre
- linfadenopatía
- hepatoesplenomegalia
- sangrado mucoso
- masa cutánea o testicular
- infiltración cutánea
- agrandamiento gingival
- dolor óseo
- cloromas cutáneos
- dolor abdominal
Факторы риска
- mayores de 65 años
- tratamiento previo con quimioterapia
- trastornos hematológicos previos
- afecciones genéticas heredadas
- anomalías cromosómicas constitucionales
- exposición a la radiación
- exposición al benceno
- exposiciones ambientales
- sexo masculino
Диагностические исследования
Исследования, которые показаны в первую очередь
- hemograma completo (HC) con diferencial
- frotis de sangre periférica
- perfil de coagulación
- electrolitos séricos y ácido úrico
- función renal
- pruebas de función hepática (PFH)
- lactato deshidrogenasa sérica
- evaluación de la médula ósea
- pruebas diagnósticas citogenéticas y moleculares
Исследования, проведение которых нужно рассмотреть
- punción lumbar
- tipificación del antígeno leucocitario humano (HLA)
- radiografía de tórax
- ecocardiograma
- ventriculografía con radionúclidos
Алгоритм лечения
LMA recién diagnosticada: apta para quimioterapia estándar de dosis intensiva
LMA recién diagnosticada: no apta para quimioterapia estándar de dosis intensiva
leucemia promielocítica aguda (LPA) de reciente diagnóstico y sin alto riesgo
leucemia promielocítica aguda (LPA) de alto riesgo recién diagnosticada
remisión completa: LMA
remisión completa: leucemia promielocítica aguda (LPA) de no alto riesgo
remisión completa: leucemia promielocítica aguda de alto riesgo (LPA)
LMA en recidiva o refractaria
leucemia promielocítica aguda (LPA) en recidiva o refractaria
Составители
Авторы
Vijaya Raj Bhatt, MBBS, MS
Associate Professor
Section Leader, Malignant Hematology
University of Nebraska Medical Center Division of Hematology-Oncology
Nebraska
NE
Раскрытие информации
VRB has participated in a Safety Monitoring Committee for Protagonist Therapeutics. He has received consulting fees from Imugene; research funding (institutional) from Abbvie, Pfizer, Incyte, Jazz, and NMDP; and drug support (institutional) from Chimerix for a trial.
Prajwal Dhakal, MBBS
Clinical Assistant Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation
University of Iowa
Iowa City
IA
Раскрытие информации
PD declares that he has no competing interests.
Выражение благодарностей
Dr Vijaya Raj Bhatt and Dr Prajwal Dhakal would like to gratefully acknowledge Dr Kavita Raj and Dr Priyanka Mehta, previous contributors to this topic.
Раскрытие информации
KR declares that she has no competing interests. PM is an author of a reference cited in this topic.
Рецензенты
Rebecca Connor, MD
Chief Fellow
Section of Hematology and Oncology
Department of Internal Medicine
Wake Forest University Baptist Medical Center
Winston-Salem
NC
Раскрытие информации
RC declares that she has no competing interests.
Roger M. Lyons, MD, FACP
Clinical Professor of Medicine
University of Texas Health Science Center
San Antonio
Cancer Care Network of South Texas
San Antonio
TX
Раскрытие информации
RML declares that he has no competing interests.
Shankaranarayana Paneesha, MD, MRCP, FRCPath
Consultant Haematologist
Department of Haematology and Stem Cell Transplantation
Heartlands Hospital
Birmingham
UK
Раскрытие информации
SP declares that he has no competing interests.
David Marks, MD, MRCP, MRCPath
Professor of Haematology & Stem Cell Transplantation
Department of Molecular and Cellular Medicine
University of Bristol
UK
Раскрытие информации
DM declares that he has no competing interests.
Список литературы
Основные статьи
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77.Полный текст Аннотация
National Cancer Comprehensive Network. NCCN guidelines: acute myeloid leukemia [internet publication].Полный текст
Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697-712.Полный текст Аннотация
Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 Aug 11;4(15):3528-49.Полный текст Аннотация
Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-43.Полный текст Аннотация
Статьи, указанные как источники
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Отличия
- Leucemia linfoblástica aguda
- Leucemia bifenotípica
- Neoplasias mieloides/linfoides con eosinofilia y genes de fusión de tirosina cinasa (MLNE, por sus siglas en inglés)
Больше ОтличияРекомендации
- Suspected cancer: recognition and referral
- NCCN guidelines: acute myeloid leukemia
Больше РекомендацииВойдите в учетную запись или оформите подписку, чтобы получить полноценный доступ к BMJ Best Practice
Использование этого контента попадает под действие нашего заявления об отказе от ответственности